Back to Report Store Home

Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies

  • Published: Jun-2016
  • Report Code: GBIHC397MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Diabetic Complications, Global, Number of Product Approvals by FDA and Five-Year Moving Average of Product Approvals (%), 1987–2012 6

Figure 2: Global, Sales Performance of First-in-Class and Non-First-in-Class Products after Marketing Approval ($m), 2016 8

Figure3: Diabetic Neuropathies, Global, Overview of Marketed Products, 2016 19

Figure 4: Diabetic Nephropathy, Global, Overview of Marketed Products, 2016 20

Figure 5: Diabetic Retinopathies, Global, Overview of Marketed Products, 2016 21

Figure 6: Diabetic Neuropathies, Global, Overview of Pipeline Products, 2016 23

Figure 7: Diabetic Neuropathies, Global, Molecular Targets in Pipeline, 2016 24

Figure 8: Diabetic Neuropathies, Global, Pipeline by Molecular Targets and Stage of Development, 2016 24

Figure 9: Diabetic Neuropathies, Global, Molecular Target Family Comparison, Pipeline and Marketed Products, 2016 25

Figure 10: Diabetic Neuropathies, Global, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets, 2016 26

Figure 11: Diabetic Neuropathies, Global, Percentage of First-in-Class Products in Pipeline by Molecular Target Family (%), 2016 27

Figure 12: Diabetic Neuropathies, Global, Percentage of First-in-Class Products in Pipeline by Stage of Development (%), 2016 27

Figure 13: Diabetic Nephropathy, Global, Overview of Pipeline Products, 2016 28

Figure 14: Diabetic Nephropathy, Global, Molecular Targets in Pipeline, 2016 29

Figure 15: Diabetic Nephropathy, Global, Pipeline by Molecular Targets and Stage of Development, 2016 29

Figure 16: Diabetic Nephropathy, Global, Molecular Target Family Comparison, Pipeline and Marketed Products, 2016 30

Figure 17: Diabetic Nephropathy, Global, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets, 2016 31

Figure 18: Diabetic Nephropathy, Global, Percentage of First-in-Class Products in Pipeline by Molecular Target Family (%), 2016 32

Figure 19: Diabetic Nephropathy, Global, Percentage of First-in-Class Products in Pipeline by Stage of Development (%), 2016 32

Figure 20: Diabetic Retinopathies, Global, Overview of Pipeline Products, 2016 33

Figure 21: Diabetic Retinopathies, Global, Molecular Targets in Pipeline, 2016 34

Figure 22: Diabetic Retinopathies, Global, Pipeline by Molecular Targets and Stage of Development, 2016 34

Figure 23: Diabetic Retinopathies, Global, Complications, Molecular Target Family Comparison, Pipeline and Marketed Products, 2016 35

Figure 24: Diabetic Retinopathies, Global, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets, 2016 36

Figure 25: Diabetic Retinopathies, Global, Percentage of First-in-Class Products in Pipeline by Molecular Target Family (%), 2016 37

Figure 26: Diabetic Retinopathies, Global, Percentage of First-in-Class Products in Pipeline by Stage of Development (%), 2016 37

Figure 27: Diabetic Complications, Global, First-in-Class Products in Pipeline (Part 1), 2016 38

Figure 28: Diabetic Complications, Global, First-in-Class Products in Pipeline (Part 2), 2016 39

Figure 29: Diabetic Complications, Global, First-in-Class Products in Pipeline (Part 3), 2016 40

Figure 30: Diabetic Complications, Global, First-in-Class Target Assessment Matrix, 2016 43

Figure 31: Diabetic Complications, Global, Pipeline Programs Targeting XXX, 2016 45

Figure 32: Diabetic Complications, Global, Pipeline Programs Targeting XXX, 2016 46

Figure 33: Diabetic Complications, Global, Pipeline Programs Targeting XXX, 2016 47

Figure 34: Diabetic Complications, Global, Pipeline Programs Targeting XXX, 2016 48

Figure 35: Diabetic Complications, Global, Pipeline Programs Targeting XXX, 2016 49

Figure 36: Diabetic Complications, Global, Pipeline Programs Targeting XXX, 2016 51

Figure 37: Diabetic Complications, Global, Pipeline Programs Targeting XXX, 2016 52

Figure 38: Diabetic Complications, Global, Pipeline Programs Targeting XXX, 2016 53

Figure 39: Diabetic Complications, Global, Deals by Stage of Development, 2006–2014 54

Figure 40: Diabetic Complications, Global, Licensing Deal Values by Stage of Development ($m), 2006–2014 55

Figure 41: Diabetic Complications, Global, Licensing Deal Value, 2006–2016 56

Figure 42: Diabetic Complications, Global, Licensing Deals by Year, 2006–2016 56

Figure 43: Diabetic Complications, Global, Licensing Deals by Stage of Development, 2006–2016 56

Figure 44: Diabetic Complications, Global, Licensing Deal Value by Stage of Development and Molecule Type, 2006–2016 57

Figure 45: Diabetic Complications, Global, Licensing Deal Value by Molecular Target, 2006–2016 57

Figure 46: Diabetic Complications, Global, Summary of Licensing Deals, 2006–2016 58

Figure 47: Diabetic Complications, Global, Co-development Deal Value, 2006–2016 59

Figure 48: Diabetic Complications, Global, Co-development Deals, 2006–2016 59

Figure 49: Diabetic Complications, Global, Co-development Deals by Stage of Development, 2006–2016 60

Figure 50: Diabetic Complications, Global, Co-development by Stage of Development and Molecule Type, 2006–2015 60

Figure 51: Diabetic Complications, Global, Co-development by Stage of Development and Molecular Target, 2006–2015 61

Figure 52: Diabetic Complications, Global, Summary of Co-development Deals, 2006-2016 62

Figure 53: Diabetic Complications, Global, First-in-Class Therapies Not Involved in Deals (Part 1), 2016 63

Figure 54: Diabetic Complications, Global, First-in-Class Therapies Not Involved in Deals (Part 2), 2016 64

Figure 55: Diabetic Complications, Global, First-in-Class Therapies Not Involved in Deals (Part 3), 2016 65

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards